Titan Pharmaceuticals
TTNP
TTNP was delisted on the 1st of October, 2025.
21 hedge funds and large institutions have $2.65M invested in Titan Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 4 closing their positions.
50% more capital invested
Capital invested by funds: $1.76M → $2.65M (+$885K)
0% less ownership
Funds ownership: 0% → 0% (-0%)
5% less funds holding
Funds holding: 22 → 21 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$43.5K |
| 2 |
WS
Wedbush Securities
Los Angeles,
California
|
+$20.1K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$10K |
| 4 |
FHA
Flagship Harbor Advisors
Boston,
Massachusetts
|
+$3.35K |
| 5 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
+$3.35K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$80K |
| 2 |
BlackRock
New York
|
-$46.9K |
| 3 |
Millennium Management
New York
|
-$43.5K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$39K |
| 5 |
SRAM
Stone Ridge Asset Management
New York
|
-$30K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Wells Fargo
San Francisco,
California
| $1K | – | – | – |
|
27
BNP Paribas Financial Markets
Paris,
France
| $2 | – | – | – |
|
|
28
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$80K | -21 | Closed |
|
|
29
Citadel Advisors
Miami,
Florida
| – | -$39K | -10 | Closed |
|
|
SRAM
30
Stone Ridge Asset Management
New York
| – | -$30K | -8 | Closed |
|
31
UBS Group
Zurich,
Switzerland
| – | -$3.35K | -1 | Closed |
|
|
KF
32
Krilogy Financial
St. Louis,
Missouri
| – | -$1K | – | – |
|
TTNP Hedge Fund Activity: Q2 2018 in Review
21 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Titan Pharmaceuticals (TTNP) for Q2 2018, worth a combined $2.65M — up 50% from $1.76M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of TTNP and 3 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 2 added.
The largest buyer was Renaissance Technologies, adding an estimated $43.5K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $80K sold.
- 21 institutional investors held Titan Pharmaceuticals (TTNP) as of Q2 2018, down from 22 in Q1 2018.
- Funds reported $2.65M of Titan Pharmaceuticals stock for Q2 2018, up 50% quarter-over-quarter.
- 3 funds opened new Titan Pharmaceuticals positions in Q2 2018 and 4 closed out, a net change of -1 holder.
- The largest Titan Pharmaceuticals buyer in Q2 2018 was Renaissance Technologies, an estimated $43.5K added.
- The largest Titan Pharmaceuticals seller in Q2 2018 was Susquehanna International Group, an estimated $80K sold.
Based on aggregated 13F filings for Q2 2018.